Article

New observations noted about circadian IOP patterns

San Francisco - Both IOP and the rate of aqueous flow follow a circadian rhythm and that has significant implications for the evaluation and treatment of patients with ocular hypertension and glaucoma, said Robert N. Weinreb, MD, director, Hamilton Glaucoma Center, and distinguished professor of ophthalmology, University of California, San Diego.

San Francisco - Both IOP and the rate of aqueous flow follow a circadian rhythm and that has significant implications for the evaluation and treatment of patients with ocular hypertension and glaucoma, said Robert N. Weinreb, MD, director, Hamilton Glaucoma Center, and distinguished professor of ophthalmology, University of California, San Diego.

Although previous concepts held that IOP peaks in the morning and so may be best measured at 8 or 10 a.m., more recent data from the evaluation of subjects in 24-hour sleep laboratories indicate that IOP is highest during the nocturnal period both in healthy individuals and patients with glaucoma. Studies of aqueous flow show that it is disproportionately represented during the day and decreases at night. Aqueous flow during the 8 hours from 10 p.m. to 6 a.m. accounts for only 17% of the day’s total, noted Dr. Weinreb.

Those findings may be expected to have important clinical implications considering that the various types of drugs used to treat glaucoma have different mechanisms of action with respect to effects on aqueous humor production and uveoscleral outflow. Supporting that hypothesis are the results of various studies that show timolol dosed in the morning was highly effective during the day but was less effective at night, while latanoprost (Xalatan, Pfizer Ophthalmics) offers effective IOP control around the clock.

“Based on the studies performed so far, it seems that a single measurement of IOP during usual office hours is insufficient for optimal glaucoma management,” Dr. Weinreb said. “We need to consider measuring IOP at various times throughout the day and measuring it in the supine position, which seems to give a better estimate of peak IOP than sitting IOP.

“In addition, if peak IOP occurs during the night, it seems likely that a lot of glaucomatous damage also occurs in the nocturnal period and we need to be using medications that are effective at lowering IOP during the night,” Dr. Weinreb said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.